Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
Study Identifier:
ACH443-018
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Elvucitabine
- Drug: Lamivudine
- Drug: Emtricitabine
Date
Sep 2006 - Dec 2008
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 60 Years
Requirements Information
Sex
Female & Male
Age
18 - 60 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Elvucitabine
- Drug: Lamivudine
- Drug: Emtricitabine
Date
Sep 2006 - Dec 2008
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 60 Years years
Requirements Information
Protocol Summary
To assess the safety of 48 weeks of treatment with 10 milligrams (mg) of elvucitabine in combination with background antiretroviral therapy (ART) in participants who completed Study ACH443-014A and meet the inclusion and exclusion criteria.
Trial Locations
Location
Status
Location
Clinical Trial Site
Atlanta, Georgia, United States, 30308
Status
N/A
Location
Clinical Trial Site
Cincinnati, Ohio, United States, 45242
Status
N/A
Location
Clinical Trial Site
Santo Domingo, Dominican Republic
Status
N/A
Location
Clinical Trial Site
Berlin, Germany
Status
N/A
Location
Clinical Trial Site
Bonn, Germany
Status
N/A
Location
Clinical Trial Site
Köln, Germany
Status
N/A